DISEASE INDICATIONS: Breast Cancer
MANUFACTURER: Roche Registration Limited
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Perjeta, also known by its generic name Pertuzumab, is a monoclonal antibody drug developed by Genentech, a member of the Roche Group. It was approved by the United States Food and Drug Administration (FDA) in 2012, marking a significant milestone in the treatment of HER2-positive breast cancer, a particularly aggressive and fast-growing form of the disease. Perjeta is often used in combination with other medications, most notably Herceptin (Trastuzumab), and chemotherapy agents like docetaxel.
